

Session 4

Knowledge Cafe



Inputs on Advancing Vaccine Development & Manufacture in Africa

The development of a strategy with national, regional, and continental partners perspectives in the context of strengthening national health security.

- **Importance of vaccine development and manufacturing capacity in Africa.**
- **AVMI Value Proposition**
- **Identifying, securing and working with Champions**
- **Developing the concept of a Ministerial Conference on Vaccine Development and Manufacture in Africa**

Importance
of
Vaccine Development
and
Manufacturing Capacity
in
Africa

TABLE 1

Key Questions

- Why is Vaccine Development and Manufacturing in Africa Important?
- Who are the Key Stakeholder who need to understand and support the above Message?
- What are the Challenges of delivering the above Message to Key Stakeholder, and how do we deliver the above Message?
- *What makes vaccines so important as product?*

TABLE 1

Why is Vaccine Development and Manufacturing in Africa Important?

Make Africa Great!

- Africa is the market
- Create jobs
- Conserve FOREX; 99% Import—*Economic/Trade Deficit*
 - ROI - *Cost-Benefit-Analysis*
- Better control of supplies for immunization
 - National Security; Reduce Dependency;
 - Sustainability
 - Donor fatigue
- Capacity Enhancement to Develop and Manufacture Vaccines that are relevant to Africa
 - Shifting Dx burden pattern
 - Large and rapidly growing population
 - Prevention, better than Cure – Long term impact, not quick fix
- Develop expertise in translational science; Skill set for other related industries
- Vaccine manufacturing is profitable
- Confidence building – Maturing to solve other problems

TABLE 1

Who are the Key Stakeholders who need to understand and support the above Message?

- **Government**
 - Ministry of Health
 - Ministry of Economic Development/Finance/Trade & Industry/Innovation
 - Ministry of State Owned Enterprises
 - Ministerial Committee
 - Investment Commission
- **Business**
 - Private Sector
 - Local (African) Pharmaceutical Enterprises
 - External Pharmaceutical Enterprises
 - World Bank; African Development Bank; IFC
- **Universities/ Medical Research Institutes**
- **Regulatory Authority**
 - NRA; RRA
- **Regional Blocs**
 - ECOWAS/EAC,SADC,
- **NEPAD**
- **African Union**
- **European Union**
- **Developmental Partners**
- **NGO/CSO**
- **The Recipient/Child/Patient**
- **Caretaker of the recipient**

TABLE 1

What are the Challenges of delivering the above Message to Key Stakeholder, and how do we deliver the above Message?

Trust & Confidence

- How to Convince? Government, Business/Investors etc.
 - **Data** Gambia/Senegal
 - Use MoH
 - Health Economist Cost of disease outbreak
 - Understand Objectives/Focus of specific Investors-*Align*
- Political Will/Commitment: (10yrs Gestation v 4yrs Political tenure)
 - Institutionalize: National level, Regional level
- Regulatory Capability: Quality v Killing initiatives
 - Harmonization of Regulatory requirements
- Clear Plan What to achieve, Why, Timeline; Mapping of Stakeholders develop relevant specific messages to each group of stakeholders
- Realistic Plan; Start Small – Pilot Project

TABLE 1

*What makes
vaccines so
important as
product*

Trust & Confidence

- It saves lives
- Ensures good Quality of Life
- Increase National Productivity
- Huge Economic loss from Morbidity & Mortality
- Complex to manufacture
- Significantly reduces Healthcare Costs
- Can eventually help control population growth